Soup to Nuts

The COVID-19 pandemic demands action on many fronts, from prevention to testing to treatment. Not content to focus its research efforts on just one, the laboratory of George Church in the Blavatnik Institute at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University is tackling the problem from seven different angles.

Read more

UTEP Researchers Develop Nanohybrid Vehicle to Optimally Deliver Drugs Into the Human Body

The researchers discovered that encapsulating ellagic acid in chitosan, a sugar, reduces its inherent cytotoxicity while enhancing its anti-oxidant properties. The chitosan shell, which makes up the hard outer skeleton of shellfish, also permits EA delivery via a rapid burst phase and a relatively slow phase.

Read more

International Collaboration for Scientific Training Launched Between The Wistar Institute and Leiden University Medical Center in the Netherlands

Wistar and Leiden University Medical Center (LUMC) formalized a memorandum of understanding between the two institutions to explore a postdoctoral training exchange program in immunology, cancer research and vaccine biology. The Wistar-Schoemaker International Postdoctoral Fellowship would bring recent Ph.D. graduates trained at LUMC to Wistar to advance their research education under the mentorship of cutting-edge biomedical research leaders.

Read more

CNS Gift to the CNS Foundation Doubles Innovative Clinical Research Initiative, Creating Annual NINDS/CNSF K12 Scholar Awards

The Congress of Neurological Surgeons Foundation (CNS Foundation) announced a second K12 award will be funded by a generous gift from the Congress of Neurological Surgeons (CNS). The award is made possible through a collaboration with the Foundation of the National Institutes of Health (FNIH) and the National Institutes of Health (NIH).

Read more

Texas Biomed continues testing Ebola therapies and vaccines showing promise in outbreak areas

In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).

Read more